| Literature DB >> 33328745 |
Qi Xu1, Fen Pan1, Yan Sun1, Chun Wang1, Yingying Shi1, Tiandong Zhang1, Fangyuan Yu1, Hong Zhang1.
Abstract
PURPOSE: To determine the epidemiology characteristics of intestinal colonization of carbapenem-resistant Enterobacteriaceae (CRE) among inpatients in a pediatric hospital in China.Entities:
Keywords: E. aerogenes; ERIC-PCR; NICU; ST4; hospitalized children; intestinal colonization
Year: 2020 PMID: 33328745 PMCID: PMC7735787 DOI: 10.2147/IDR.S275549
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Figure 1Distribution of CRE strains in different departments.
The Clinical Characteristics of CRE Carriers
| Characteristics | Total | P-value* | |||
|---|---|---|---|---|---|
| Age(m)a | 2(0.7–12) | 0.9(0.4–1) | 16(5–60) | 3(0.7–12.5) | 0.000 |
| Male gender | 58(64.4%) | 16(53.3%) | 17(68.0%) | 15(65.2%) | 0.490 |
| Length of stay (d)a | 31(16–74) | 30(15–74) | 35(25–77) | 25(9–77) | 0.012 |
| Length from admission to CRE | 12(3–34) | 15(3–32) | 8(3–48) | 9(3–26) | 0.075 |
| Gastrointestinal Diseases | 20(22.2%) | 5(16.7%) | 6(24.0%) | 5(21.7%) | 0.787 |
| Immunocompromised | 11(12.2%) | 3(10.0%) | 4(16.0%) | 2(8.7%) | 0.691 |
| NRDS | 7(12.2%) | 1(3.3%) | 2(8.0%) | 3(13.0%) | 0.420 |
| CHD | 4(4.4%) | 1(3.3%) | 0(0.0%) | 1(4.3%) | 0.600 |
| Intubation/Mechanical ventilate | 52(57.8%) | 21(70.0%) | 11(44.0%) | 16(69.6%) | 0.112 |
| Lumbar puncture | 34(37.8%) | 14(46.7%) | 9(36.0%) | 8(34.8%) | 0.612 |
| Central venous catheter | 27(30.0%) | 11(36.7%) | 5(20.0%) | 9(39.1%) | 0.363 |
| Surgery | 6(6.7%) | 3(10.0%) | 1(4.0%) | 1(4.3%) | 0.592 |
| Urinary catheterization | 5(5.4%) | 2(6.7%) | 2(8.0%) | 1(4.3%) | 0.873 |
| Abdominal drainage | 2(2.2%) | 0(0.0%) | 1(4.0%) | 0(0.0%) | 0.342 |
| β-lactam/β-lactamase inhibitor | 47(52.2%) | 13(43.3%) | 10(40.0%) | 8(34.8%) | 0.809 |
| Cephalosporins | 32(35.6%) | 11(36.7%) | 9(36.0%) | 9(39.1%) | 0.973 |
| Carbapenems | 15(16.7%) | 5(16.7%) | 6(24.0%) | 2(8.7%) | 0.364 |
| Fluoroquinolones | 6(6.7%) | 4(13.3%) | 2(8.0%) | 0(0.0%) | 0.195 |
| Vancomycin | 6(6.7%) | 0(0.0%) | 4(16.0%) | 1(4.3%) | 0.049 |
| Fosfomycin | 5(5.6%) | 2(6.7%) | 3(12.0%) | 0(0.0%) | 0.237 |
| Cure | 73(81.1%) | 25(83.3%) | 18(72.0%) | 20(87.0%) | 0.381 |
| Death | 6(6.7%) | 3(10.0%) | 3(12.0%) | 0(0.0%) | 0.247 |
Notes: a Median and interquartile ranges (25th and 75th percentile); b Invasive testing or treatment before CRE detected; c At least 1 antibiotic dose used before CRE detected. * A comparison between three groups. A P-value of <0.05 was considered statistically significant. The P-value (sig) of age between E. aerogenes and K. pneumoniae carriers, E. aerogenes and E. coli carriers, K. pneumoniae and E. coli carriers were 0.000, 0.006, and 0.018, respectively. The P-value (sig) of Length of stay between E. aerogenes and K. pneumoniae carriers, E. aerogenes and E. coli carriers, K. pneumoniae and E. coli carriers were 0.019, 0.800, and 0.028, respectively.
Abbreviations: m, month; d, day; PICU, pediatric intensive care unit; NICU, neonatal intensive care unit; NRDS, neonatal respiratory distress syndrome; CHD, Chronic Heart Disease.
The Clinical Characteristics of CRE Carriers in NICU
| Characteristics | Total | P-value | ||
|---|---|---|---|---|
| Birth weight (g)d | 1590(1260–1822) | 1630(1172–1985) | 1360(1260–1590) | 0.002 |
| Gestational age (w) | 31(30–33) | 31(30–34) | 31(29–32) | 0.003 |
| Apgar score at 5 minutesd | 8(5–9) | 8(5–9) | 8(6.5–9) | 0.624 |
| Breast feeding | 28(68.3%) | 12(48.0%) | 5(50.0%) | 1.000 |
| Mixed feeding | 8(19.5%) | 5(20.0%) | 2(20.0%) | 1.000 |
| Not started to feed | 5(12.2%) | 2(8.0%) | 2(20.0%) | 0.674 |
| Pre-eclampsia | 10(24.4%) | 6(24.0%) | 3(30.0%) | 1.000 |
| Gestational diabetes | 9(22.0%) | 7(28.0%) | 2(20.0%) | 0.951 |
| PROM | 4(9.8%) | 1(4.0%) | 2(20.0%) | 0.390 |
| Hypothyroidism | 2(4.9%) | 1(4.0%) | 1(10.0%) | 1.000 |
| Dexamethasone | 8(19.5%) | 4(16.0%) | 2(20.0%) | 1.000 |
| Antihypertensives | 5(12.2%) | 3(12.0%) | 2(20.0%) | 0.939 |
| Antibiotics | 4(9.8%) | 3(12.0%) | 0(0.0%) | 0.633 |
| Insulin | 3(7.3%) | 2(8.0%) | 1(10.0%) | 1.000 |
| Euthyrox | 2(4.9%) | 1(4.0%) | 1(10.0%) | 1.000 |
| Others | 7(17.1%) | 5(20.0%) | 2(20.0%) | 1.000 |
| Cesarean delivery | 25(61.0%) | 15(60.0%) | 6(60.0%) | 1.000 |
| Natural vaginal delivery | 15(36.6%) | 9(36.0%) | 4(40.0%) | 1.000 |
Notes: dMedian and interquartile ranges (25th and 75th percentile); A P-value of <0.05 was considered statistically significant.
Abbreviations: w, week; PROM: premature rupture of membranes.
Antimicrobial Susceptibility and MIC Distributions of CRE Isolates
| CAZ | >256 | >256 | 100.0 | >256 | >256 | 100.0 | >256 | >256 | 100.0 |
| CTX | >128 | >128 | 100.0 | >128 | >128 | 100.0 | >128 | >128 | 100.0 |
| FEP | >256 | >256 | 98.9 | >256 | >256 | 100.0 | 128 | >256 | 100.0 |
| ETP | 32 | >128 | 100.0 | 16 | 128 | 100.0 | 64 | >128 | 100.0 |
| IPM | 32 | 128 | 97.8 | 32 | 128 | 97.1 | 32 | 128 | 100.0 |
| MEM | 32 | 128 | 98.9 | 32 | 128 | 100.0 | 64 | 256 | 100.0 |
| CSL | >256 | >256 | 98.9 | >256 | >256 | 100.0 | >256 | >256 | 100.0 |
| TZP | >256/4 | >256/4 | 98.9 | >256/4 | >256/4 | 100.0 | >256/4 | >256/4 | 100.0 |
| CIP | 8 | 64 | 93.3 | 4 | 64 | 94.3 | 64 | 128 | 100.0 |
| SXT | 16/304 | >32/608 | 53.3 | 2/38 | 16/304 | 50.0 | 16/304 | >32/608 | 66.7 |
| AMK | <2 | >256 | 25.6 | <2 | >256 | 15.7 | >256 | >256 | 83.3 |
| GEN | <1 | >128 | 40.0 | <1 | >128 | 31.4 | >128 | >128 | 91.7 |
| ATM | 128 | >256 | 88.9 | 128 | >256 | 85.7 | 128 | >256 | 100.0 |
| CZA | 64/4 | >128/4 | 82.2 | 64/4 | >128/4 | 92.9 | 2/4 | >128/4 | 33.3 |
| FOS | 32 | >512 | 22.2 | 32 | >512 | 18.6 | 64 | >512 | 33.3 |
| COL | 1 | >4 | 26.7 | 1 | >4 | 25.7 | 2 | >4 | 33.3 |
| TGC | 1 | 1 | 1.1 | 1 | 1 | 1.4 | 1 | 1 | 0.0 |
Abbreviations: CAZ, ceftazidime; CTX, cefotaxime; FEP, cefepime; ETP, ertapenem; IPM, imipenem; MEM, meropenem; CSL, cefoperazone-Sulbactam; TZP, piperacillin–tazobactam; CIP, ciprofloxacin; SXT, trimethoprim-sulfamethoxazole; AMK, amikacin; GEN, gentamicin; ATM, aztreonam; CZA, ceftazidime-avibactam; FOS, fosfomycin; COL, colistin; TGC, tigecycline; R, resistant.
Figure 2Dendrogram obtained from ERIC-PCR fingerprinting and Plasmid Replicon Profile of E. aerogenes (A), K. pneumoniae (B) and E. coli (C) isolates.